These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 12435836)

  • 61. Similarities and differences by race/ethnicity in changes of HIV seroprevalence and related behaviors among drug injectors in New York City, 1991-1996.
    Friedman SR; Chapman TF; Perlis TE; Rockwell R; Paone D; Sotheran JL; Des Jarlais DC
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):83-91. PubMed ID: 10534151
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HIV-1 infection in injection drug users.
    Cohn JA
    Infect Dis Clin North Am; 2002 Sep; 16(3):745-70. PubMed ID: 12371125
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Syringe type and drug injector risk for HIV infection: a case study in Texas.
    Zule WA; Desmond DP; Neff JA
    Soc Sci Med; 2002 Oct; 55(7):1103-13. PubMed ID: 12365524
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Networks, resources and risk among women who use drugs.
    Miller M; Neaigus A
    Soc Sci Med; 2001 Mar; 52(6):967-78. PubMed ID: 11234869
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Harm reduction in the health care system: the legality of prescribing and dispensing syringes to drug users.
    Burris S; Lurie P; Ng M
    Health Matrix Clevel; 2001; 11(1):5-64. PubMed ID: 11345676
    [No Abstract]   [Full Text] [Related]  

  • 66. Drug use and HIV risks among African-American, Mexican-American, and Puerto Rican drug injectors.
    Estrada AL
    J Psychoactive Drugs; 1998; 30(3):247-53. PubMed ID: 9798790
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Transitions from injecting to non-injecting drug use: potential protection against HCV infection.
    Des Jarlais DC; McKnight C; Arasteh K; Feelemyer J; Perlman DC; Hagan H; Cooper HL
    J Subst Abuse Treat; 2014 Mar; 46(3):325-31. PubMed ID: 24161262
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Once more unto the breach: controlling hepatitis C in injecting drug users.
    Wodak A; Crofts N
    Addiction; 1996 Feb; 91(2):181-4. PubMed ID: 8835275
    [No Abstract]   [Full Text] [Related]  

  • 69. [New tools for preventing and evaluating risk practices for hepatitis C transmission among injection drug users: some reflections on injection rooms and the measurement of risk-taking behaviors].
    Aubisson S; Carrieri P; Lovell AM; Ben Diane MK; Peretti-Watel P; Spire B
    Rev Epidemiol Sante Publique; 2006 Jul; 54 Spec No 1():1S69-1S75. PubMed ID: 17073132
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safer injection facilities (SIFs) for injection drug users (IDUs) in Canada. A review and call for an evidence-focused pilot trial.
    Fischer B; Rehm J; Kim G; Robins A
    Can J Public Health; 2002; 93(5):336-8. PubMed ID: 12353452
    [No Abstract]   [Full Text] [Related]  

  • 71. Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention.
    Strathdee SA; Shoptaw S; Dyer TP; Quan VM; Aramrattana A;
    Curr Opin HIV AIDS; 2012 Jul; 7(4):320-5. PubMed ID: 22498479
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oregon's exclusion of syringes from its 1987 drug paraphernalia law was an HIV prevention measure.
    Wright LN; Gebbie KM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 18 Suppl 1():S144-5. PubMed ID: 9663641
    [No Abstract]   [Full Text] [Related]  

  • 73. Overview of HIV among injection drug users in New York City: critical next steps to eliminate racial/ethnic disparities.
    Amesty S; Rivera AV; Fuller CM
    Subst Use Misuse; 2011; 46(2-3):285-94. PubMed ID: 21303248
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia.
    Aitken C; Delalande C; Stanton K
    Drug Alcohol Depend; 2002 Feb; 65(3):303-8. PubMed ID: 11841901
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Invited commentary: needle exchange--no help for hepatitis?
    Moss AR; Hahn JA
    Am J Epidemiol; 1999 Feb; 149(3):214-6; discussion 217-8. PubMed ID: 9927215
    [No Abstract]   [Full Text] [Related]  

  • 76. Health Equity, Social Justice, and HIV in Rhode Island: A Contemporary Challenge.
    Bertrand T; Chan PA; Howe K; Comella J; Marak T; Bandy U
    R I Med J (2013); 2016 Nov; 99(11):21-24. PubMed ID: 27801915
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Updating the infection risk reduction hierarchy: preventing transition into injection.
    Vlahov D; Fuller CM; Ompad DC; Galea S; Des Jarlais DC
    J Urban Health; 2004 Mar; 81(1):14-9. PubMed ID: 15047779
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections.
    Fu R; Gutfraind A; Brandeau ML
    Math Biosci; 2016 Mar; 273():102-13. PubMed ID: 26775738
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C.
    Latka MH; Hagan H; Kapadia F; Golub ET; Bonner S; Campbell JV; Coady MH; Garfein RS; Pu M; Thomas DL; Thiel TK; Strathdee SA
    Am J Public Health; 2008 May; 98(5):853-61. PubMed ID: 18382005
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Syringe access programs.
    J Assoc Nurses AIDS Care; 2012; 23(3):272-4. PubMed ID: 22645744
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.